Recombinant human VEGF Receptor 2 protein (ab42614)
Key features and details
- Expression system: Baculovirus infected insect cells
- Purity: > 90% SDS-PAGE
- Active: Yes
- Suitable for: Inhibition Assay
製品の詳細
-
製品名
Recombinant human VEGF Receptor 2 protein
VEGF Receptor 2 タンパク質・ペプチド 製品一覧 -
生理活性
40 U/µg. One unit is defined as the amount of enzyme that will transfer 1 pmol phosphate to Tyr substrate per minute at pH 7.4 and 30°C. Assay buffer: 50 mM HEPES, pH 7.4, 3 mM MgCl2, 3 mM MnCl2, 1 mM DTT, 3 µM Na-orthovanadate, 0.5 mM ATP, 30 µg/ml Poly (Glu:Tyr)4:1 substrate and 1 µg/ml recombinant VEGF Receptor 2.
-
精製度
> 90 % SDS-PAGE.
Affinity purified. -
発現系
Baculovirus infected insect cells -
タンパク質長
Full length protein -
Animal free
No -
由来
Recombinant -
-
生物種
Human -
領域
805 to 1356
-
特性
Our Abpromise guarantee covers the use of ab42614 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
-
アプリケーション
Inhibition Assay
-
製品の状態
Liquid -
備考
This protein was expressed using a Baculovirus infected Sf9 cell expression system. -
Concentration information loading...
前処理および保存
-
保存方法および安定性
Shipped on Dry Ice. Upon delivery aliquot. Store at -80°C. Avoid freeze / thaw cycle.
pH: 8.00
Constituents: 0.0462% (R*,R*)-1,4-Dimercaptobutan-2,3-diol, 0.395% Tris HCl, 0.05% Tween, 50% Glycerol (glycerin, glycerine), 0.58% Sodium chlorideThis product is an active protein and may elicit a biological response in vivo, handle with caution.
関連情報
-
別名
- CD309
- CD309 antigen
- EC 2.7.10.1
see all -
機能
Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. -
関連疾患
Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma. -
配列類似性
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
翻訳後修飾
Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214. -
細胞内局在
Membrane. - Information by UniProt
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (0)
ab42614 は論文での使用が確認できていません。